Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649433 | 0.94 | MDM2 (0.44) | MDM2TLR2KLKB1SIRT2SIRT1 | |
| SCHEMBL29649605 | 0.88 | CASP3 (0.40) | CASP3MDM2TLR2SIRT2SIRT1 | |
| SCHEMBL29590265 | 0.86 | MDM2 (0.39) | CASP3MDM2SIRT2SIRT1SIRT3 | |
| SCHEMBL29649526 | 0.84 | MDM2 (0.45) | MDM2TLR2SIRT2SIRT1SIRT3 | |
| SCHEMBL31681574 | 0.84 | MDM2 (0.45) | MDM2TLR2SIRT2SIRT1SIRT3 | |
| SCHEMBL25361941 | 0.84 | MDM2 (0.43) | MDM2TLR2SIRT2SIRT1SIRT3 | |
| SCHEMBL25361944 | 0.84 | MDM2 (0.43) | MDM2TLR2SIRT2SIRT1SIRT3 | |
| SCHEMBL30479657 | 0.84 | CASP3 (0.53) | CASP3MDM2TLR2 | |
| SCHEMBL30518584 | 0.82 | PTPN1 (0.45) | MDM2SIRT2SIRT1 | |
| SCHEMBL29649513 | 0.81 | KLKB1 (0.42) | KLKB1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |